<DOC>
	<DOCNO>NCT02944162</DOCNO>
	<brief_summary>The purpose clinical trial study genetically engineer NK92 cell therapy treat patient CD33 positive acute myeloid leukemia relapse ( stem cell transplantation intensive chemotherapy ) refractory chemotherapy .</brief_summary>
	<brief_title>CAR-pNK Cell Immunotherapy Relapsed/Refractory CD33+ AML</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : Determine safety feasibility chimeric antigen receptor NK92 cell transduce anti-CD33 vector ( referred anti-CD33 CAR-NK cell ) . SECONDARY OBJECTIVES : I . For patient detectable disease , measure anti-leukemia response due anti-CD33 CAR-NK cell infusion . II . For patient store accessible leukemia blast , determine leukemia cell kill anti-CD33 CAR-NK vitro . III . Determine cellular humoral host immunity develop murine anti-CD33 . OUTLINE : Patients assign 1 group accord order enrollment . Patients receive anti-CD33 CAR-NK ( couple CD28 , CD137 CD3 zeta signal domain ) vector-transduced NK92 cell line day 0,3 , 5 absence disease progression unacceptable toxicity . After completion study treatment , patient follow intensively 6 month , every 3 month 2 year , annually thereafter 10 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>1 . Male female subject CD33+ acute myeloid leukemia patient available curative treatment option ( autologous allogeneic SCT ) limit prognosis ( &gt; 12 week &lt; 2 year survival ) currently available therapy enrol . 2 . CD33+ acute myeloid leukemia CR ( complete remission ) achieve least 2 prior combination chemotherapy regimens . 3 . AML CR2 CR3 eligible allogeneic SCT age , comorbid disease , lack available family member unrelated donor . 4 . Less 1 year last chemotherapy progression ( i.e . recent progression free interval &lt; 1 year ) . 5 . Relapsed prior autologous allogenic SCT . AML patient relapse residual disease least 1 prior therapy eligible allogeneic SCT . 6 . Residual disease primary therapy eligible autologous SCT . 7 . All patient must also meet follow criterion : Expected survival &gt; 12 week . Creatinine &lt; 2.5 mg/dl ALT ( alanine aminotransferase ) /AST ( aspartate aminotransferase ) &lt; 3x normal Bilirubin &lt; 2.0 mg/dl Any relapse prior SCT make patient eligible regardless prior therapy . Adequate venous access apheresis , contraindication leukapheresis . Ability give inform consent . 1 . Pregnant nursing woman may participate . 2 . Active HIV , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection time screen . 3 . Serious illness medical condition would permit patient manage accord protocol , include active uncontrolled infection , major cardiovascular , coagulation disorder , respiratory immune system , myocardial infarction , cardiac arrhythmia , obstructive/restrictive pulmonary disease , psychiatric emotional disorder . 4 . History severe immediate hypersensitivity agent include cyclophosphamide , fludarabine , aldesleukin . 5 . Concurrent use systemic steroid . Recent current use inhale steroid exclusionary . 6 . The existence unstable active ulcer gastrointestinal bleeding . 7 . Patients need anticoagulant therapy ( warfarin heparin ) . 8 . Patients need longterm antiplatelet therapy ( aspirin dose &gt; 300mg/d ; clopidogrel dose &gt; 75mg/d ) .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>CD33</keyword>
	<keyword>CAR-NK</keyword>
</DOC>